Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Feb 2;14(2):e21844.
doi: 10.7759/cureus.21844. eCollection 2022 Feb.

Antinuclear Antibody (ANA) and Anti-Mi-2-Alpha Positive Dermatomyositis Hinting a Cancer Diagnosis

Affiliations
Case Reports

Antinuclear Antibody (ANA) and Anti-Mi-2-Alpha Positive Dermatomyositis Hinting a Cancer Diagnosis

Mariana Pacheco et al. Cureus. .

Abstract

Dermatomyositis (DM) is a relatively uncommon inflammatory myopathy that has been linked to cancer. We report the case of an 81-year-old woman with cecum adenocarcinoma presenting with antinuclear antibody (ANA) and anti-Mi-2-alpha antibody-positive DM. The patient complained of anorexia, symmetric proximal muscle weakness and skin rash and presented with elevated muscle enzymes. A skin and muscle biopsy supported the diagnosis of DM as did the limbs magnetic resonance imaging (MRI) and electromyography. A diagnosis of localized adenocarcinoma of the cecum was made through colonoscopy and the patient was successfully surgically managed, with decreasing muscle enzymes at discharge and gradual recovery of muscle strength. The presence of both ANA and anti-Mi-2 autoantibodies has classically been described as comprising a better prognosis with a lower risk of underlying malignancy. This case highlights the importance of pursuing a cancer diagnosis in elderly patients presenting with DM even in presence of less predisposing immunological profiles.

Keywords: adult onset; anti-mi2 alpha; antinuclear antibody; cancer; dermatomyositis.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Dermatomyositis skin rash
(a) V-sign and heliotrope/facial erythema that involves nasolabial folds. (b) Gottron sign: extensor surface of the elbow presenting erythematous and scaling plaques. (c) Facial erythema that involves nasolabial folds. (d) Gottron sign: erythematous patches on the extensor surfaces of the joints of the hands with periungual erythema.
Figure 2
Figure 2. MRI - T2-weighted images presenting hyperintense signal throughout the affected muscles and peri-muscular oedema
(a) Periscapular muscles in coronal view. (b) Thigh muscles in sagittal view. (c) Hip muscles in coronal view - gluteal aspect. (d) Thigh muscles in axial view.

References

    1. Polymyositis and dermatomyositis. Dalakas MC, Hohlfeld R. Lancet Lond Engl. 2003;362:971–982. - PubMed
    1. Cutaneous manifestations of dermatomyositis and their management. Callen JP. Curr Rheumatol Rep. 2010;12:192–197. - PubMed
    1. Evaluation and treatment of inflammatory myopathies. Amato AA, Barohn RJ. J Neurol Neurosurg Psychiatry. 2009;80:1060–1068. - PubMed
    1. Interstitial lung disease in polymyositis and dermatomyositis. Marie I, Hachulla E, Chérin P, et al. Arthritis Rheum. 2002;47:614–622. - PubMed
    1. Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. Lu X, Yang H, Shu X, et al. PLoS One. 2014;9:0. - PMC - PubMed

Publication types

LinkOut - more resources